Company: BDRX
Filing Date: 2025-01-28
Form Type: 424B3
Source: 0001214659-25-001409
Chunk: 248

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-28
Form: 424B3
Chunk 248
---
 Warrants,
May Private Placement Warrants and May Armistice Warrants will expire five and one-half years from the initial exercise date, and the
Wainwright October Warrants and Wainwright May Warrants will expire on October 22, 2024 and May 18, 2025, respectively. The holder shall
deliver the aggregate exercise price for the Depositary Shares specified in the exercise notice within two trading days following the
date of exercise (subject to the ‘cashless exercise’ arrangements described below).

Cashless Exercise. With respect to the October Private Placement Warrants and Wainwright October Warrants, if, more than six months after
the date of issuance of such warrants, there is no effective registration statement registering, or no current prospectus available for,
the resale of the Depositary Shares underlying such warrants, the holder may exercise the warrant, in whole or in part, on a cashless
basis. With respect to the May Private Placement Warrants and Wainwright May Warrants, if there is no effective registration statement
registering, or no current prospectus available for, the resale of the Depositary Shares underlying such warrants, the holder may exercise
the warrant, in whole or in part, on a cashless basis.

| 123 |

Exercise Price. The exercise price of (i) each October Private Placement Warrant and Wainwright October Warrant is $8,000.00 and $250,000.00
per Depositary Share, respectively and (ii) each May Private Placement Warrant, May Armistice Warrant and Wainwright May Warrant is $82,000.00,
$8,000.00 and $82,500.00 per Depositary Share, respectively, each subject to the ‘cashless exercise’ arrangements described
above and to adjustment as described below.

Beneficial Ownership Limitation. A holder shall have no right to exercise any portion of a warrant, to the extent that, after giving effect
to such exercise, such holder, together with such holder’s affiliates, and any persons acting as a group together with such holder
or any such affiliate, would beneficially own in excess of, at the initial option of the holder thereof, 4.99% or 9.99%, as applicable,
of the number of Ordinary Shares outstanding immediately after giving effect to the issuance of the Ordinary Shares underlying the Depositary
Shares upon such exercise. The holder of the warrant, upon notice to us, may increase or decrease